Most Popular

ARUP maintains that the FDA’s rule will limit access to testing, stifle innovation, and increase healthcare costs.

An expert in TAR DNA-binding protein of 43 kDa (TDP-43), neuropathologist Qinwen Mao, MD, PhD, subspecialty director of Neuropathology at ARUP, is working to identify biomarkers that predict the presence of TDP-43 pathology to contribute to the diagnosis of frontotemporal lobar degeneration (FTLD) and Alzheimer’s disease.

Nicola Longo, MD, PhD, has spent more than 20 years at University of Utah Health and ARUP Laboratories treating patients in his clinic and working with wife Marzia Pasquali, PhD, FACMG, to advance the diagnosis of inherited metabolic disorders.

Representative Blake Moore (R-Utah, District 1) speaks during a House Committee on Ways and Means hearing held at ARUP Laboratories. Pictured from left to right are Celeste Maloy (R-Utah, District 2), Burgess Owens (R-Utah, District 4), Moore, Jason Smith (R-Missouri, District 8), and Brad Wenstrup, MD (R-Ohio, District 2).

ARUP Laboratories has filed a declaration supporting a lawsuit against the FDA brought by the American Clinical Laboratory Association.

ARUP survey shows “profound” concern within the lab community about the FDA’s proposed rule.

Digitally colorized transmission electron microscopic image of avian influenza A (H5N1) virus particles (in gold), grown in Madin-Darby canine kidney (MDCK) epithelial cells (in green).

A better estimate of menopausal status will help providers and patients address both the symptoms of menopause and the associated risks, such as cardiovascular disease and osteoporosis.

The connectivity platform LKOrbit streamlines test ordering, reporting, and billing for laboratory outreach operations.

Susan Driggs, a medical laboratory scientist in ARUP’s University of Utah Hospital Clinical Laboratory, has worked in the same lab since the 1970s, before ARUP was founded.

Rep. Blake Moore (R-UT) and other members of the Ways and Means Committee’s Health Subcommittee will participate in a field hearing on July 12 at ARUP Laboratories.

Jan Wintch, CQA(ASQ), senior quality and regulatory affairs specialist, has worked at ARUP since the company was created in 1984. Forty years later, she said she is still learning new things every day.

Dipanwita Banerjee, MS, joined ARUP in 2019 to follow her desired career path after more than 10 years away from the laboratory.

A new test that ARUP offers for preeclampsia risk measures the ratio between two angiogenic factors (sFlt-1 and PlGF) that are produced by the placenta and are involved in the pathophysiology of preeclampsia.

Jonathan Genzen, MD, PhD, ARUP’s chief medical officer and senior director of governmental affairs, and Jonathan Carr, JD, chief compliance officer, discuss the FDA’s final rule on LDTs.

ARUP offers returnships for people from a variety of professional backgrounds who have taken a break from their careers for at least one year. Dipanwita Banerjee, MS, associate scientist, benefited from one such program before joining ARUP.

Karen Brisendine currently works as a technologist in ARUP’s Mycology Acid-Fast Bacilli (AFB) Lab, but she has worked in many departments at ARUP since she started with the company at its founding in 1984. Along the way, she has learned more about herself and discovered a passion for laboratory science.

ARUP medical directors and scientists, including (from left to right) Sherin Shaaban, MD, PhD, FACMG; Yuan Ji, PhD, MBA, DABCP, FACMG; and Hunter Best, PhD, FACMG, along with others, will present their latest research and share insights for current and future geneticists at the Annual Clinical Genetics Meeting in March.